Cytek Biosciences, Inc.

Cytek Biosciences, Inc. (CTKB) operates as a cell analysis solutions company, primarily leveraging its patented Full Spectrum Profiling (FSP) technology to distinguish fluorescent tags on single cells ¹. The company's core business revolves around developing and manufacturing high-resolution, high-content, and high-sensitivity cell analysis tools for biomedical research and clinical applications ¹. CTKB aims to become the premier cell analysis company through continuous innovation ¹. The company generates revenue from both product sales, including instruments, accessories, and consumables like reagents, and service revenue from post-warranty contracts, installations, and repairs ⁷⁵. Primary customer segments include pharmaceutical companies, biopharma companies, academic research centers, and contract research organizations (CROs) ⁴. Direct sales accounted for 73% of total revenue in 2025, with distributors contributing 27% ⁷².

The company's FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, are designed to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers ⁴. These systems address limitations of other technologies by offering higher multiplexing, exquisite sensitivity, flexibility, and efficiency at a lower cost for performance ⁴. The Cytek Aurora and Cytek Aurora Evo systems are available with three to five lasers and can detect 50 biomarkers in one sample tube, while the Northern Lights system offers one to three lasers and can detect over 24 biomarkers ⁷. The Cytek Aurora Evo system, launched in May 2025, enhances capabilities with high-throughput at high resolution, supporting sample flow rates up to 200 µL/min, automated startup/shutdown, and integrated APD module for small particle and large cell resolution ⁷. The Aurora CS system, a cell sorter launched in June 2021, also leverages FSP technology to isolate living cell populations with the same parameter count and sensitivity as the Aurora analyzer systems ⁷. All FSP systems are supported by proprietary SpectroFlo software, reagents, and service offerings ⁴.

In addition to the FSP portfolio, CTKB offers conventional flow and image-based flow cytometry instrumentation and related products and services under the Amnis and Guava brands, acquired in February 2023 ⁵. Amnis instruments are used for cell morphology, intracellular translocation, and cell-cell interaction studies, while Guava flow cytometers provide cost-effective, entry-level options for applications like cell counting and lower-plex immunophenotyping ⁵. The Cytek Muse Micro cell analyzer, launched in March 2025, is an affordable benchtop device with a 488 nm blue laser and five parameters, designed for diverse testing and research environments including drug discovery and bioprocessing ⁸. The Cytek Orion reagent cocktail preparation system automates antibody cocktail preparation for flow cytometry, handling up to 60 individual antibodies ⁸. The company also offers cFluor reagent products and immunoprofiling kits, including a 14-color kit, a 25-color assay, a 13-color human B cell monitoring kit, a 20-color panel for acute myeloid leukemia, and a 24-color mouse immunoprofiling panel, many of which are optimized for FSP systems ⁹.

For the fiscal year ended December 31, 2025, total revenue, net, was $201.5 million ⁵, representing a 1% increase from $200.5 million in 2024 ⁷⁷. Product revenue decreased by $9.0 million, or 6%, to $144.2 million in 2025 from $153.2 million in 2024 ⁷⁷. Service revenue increased by $10.1 million, or 21%, to $57.3 million in 2025 from $47.190 million in 2024 ⁷⁷. Total cost of sales increased by $7.7 million, or 9%, to $97.033 million in 2025 from $89.347 million in 2024 ⁷⁸. Gross profit was $104.460 million in 2025, down from $111.106 million in 2024 ⁷⁸, resulting in a gross margin of 52% in 2025, compared to 55% in 2024 ⁷⁸. Operating expenses totaled $144.844 million in 2025, up from $131.629 million in 2024 ⁷⁶. Net loss for 2025 was $66.5 million, compared to a net loss of $6.0 million in 2024 ⁵. Basic and diluted EPS were both $(0.52) in 2025, versus $(0.05) in 2024 ⁹⁰. Net cash used in operating activities was $4.7 million in 2025, a decrease from $25.4 million provided by operating activities in 2024 ⁸². Cash and cash equivalents and short-term investments were $261.5 million as of December 31, 2025, down from $277.9 million as of December 31, 2024 ⁵. Total liabilities were $119.803 million as of December 31, 2025, compared to $103.763 million as of December 31, 2024 ⁸⁹. Long-term debt was $0.525 million as of December 31, 2025, down from $1.050 million as of December 31, 2024 ⁸⁹.

Year-over-year, total revenue increased by $1.0 million, or 1%, in 2025 compared to 2024 ⁷⁷. This was primarily driven by a $10.1 million, or 21%, increase in service revenue, offset by a $9.0 million, or 6%, decrease in product revenue ⁷⁷. The decline in product revenue was mainly due to a 6.0% decrease in unit volumes for spectral and imaging products, including the Cytek Aurora, Northern Lights, Aurora CS, and ImageStream systems, partially offset by growth in reagent revenue ⁷⁷. The increase in service revenue was attributed to the growing installed base of instruments with expiring warranties, leading to more contract and time-and-material service revenue ⁷⁷. Total cost of sales increased by $7.7 million, or 9%, in 2025, primarily due to higher service revenue and associated service material, headcount, and overhead costs ⁷⁸. Product cost of sales increased due to higher tariff costs and overhead from transitioning a manufacturing facility overseas, despite lower material costs from reduced instrument volume ⁷⁸. Product gross margin decreased from 55% in 2024 to 52% in 2025, while service gross margin decreased from 57% in 2024 to 52% in 2025 ⁷⁸. Research and development expenses decreased by $2.9 million, or 7%, in 2025, due to efforts to streamline and focus activities ⁷⁹. Sales and marketing expenses remained relatively flat, increasing by $0.326 million, or 1%, due to commercial team reorganization ⁷⁹. General and administrative expenses increased by $15.8 million, or 37%, primarily due to higher patent litigation expenses, compensation, sales and use tax, software expenses, and a lower benefit from a change in estimate of the BD royalty settlement liability ⁷⁹. The net loss widened significantly from $6.0 million in 2024 to $66.5 million in 2025, largely due to a $33.1 million valuation allowance against deferred tax assets in 2025, lower gross profit, and increased operating expenses ⁷².

During 2025, the company launched the Cytek Aurora Evo system in May ⁷ and the Cytek Muse Micro cell analyzer in March ⁸. The Enhanced Small Particle (ESP) Detection Option was launched for the Cytek Aurora and Northern Lights systems in May 2024, and for the Cytek Aurora CS system in November 2024 ⁷. In November 2023, the company purchased a new building in Wuxi, China, and relocated substantially all Wuxi operations to this new facility in January 2024 ¹¹. A new manufacturing facility in Singapore commenced operations in March 2025 ¹¹. The Northern Lights-CLC system received IVDR compliance registration in the European Union in November 2023 and is registered as a Class II In Vitro Diagnostic Medical Device in China ⁷. In November 2025, the company became aware of a security incident affecting certain Sensitive Information, including employee personal information ⁴¹. The 2022 Sales Agreement for an "at-the-market" offering program, which had authorized up to $150.0 million of common stock sales, expired in August 2025 without any sales being made ⁸¹. Consequently, $0.7 million in prepaid offering costs were expensed in the third quarter of 2025 ⁸¹. The company repurchased 3,292,588 shares of common stock for approximately $15.1 million at an average price of $4.56 per share in 2025 under a program that expired on December 31, 2025, with $35.0 million remaining authorized ⁸¹.

The company anticipates continuing to expend significant amounts of cash in the foreseeable future as it invests in research and development of product offerings, commercialization of new products and services, and expansion into new markets ⁸⁰. Future capital requirements will depend on revenue, R&D efforts, timing and extent of additional capital expenditures for existing and new facilities, manufacturing operations, expansion of sales and marketing, and new product introductions ⁸⁰. The company expects to make additional capital expenditures during the next 12 months, primarily for manufacturing equipment and R&D investment ⁸⁰. Based on the current business plan, existing cash and cash equivalents and anticipated cash flows from operations are expected to be sufficient to meet working capital and capital expenditure needs for at least the next 12 months ⁸⁰.

A major growth area for the company is accelerating the adoption of its solutions by maximizing the effectiveness of its sales infrastructure, including sales representatives, technical applications specialists, and customer support staff, and increasing marketing efforts ⁶. This investment will also support entry into new markets as new solutions and applications are rolled out ⁶. The company plans to continue to innovate and offer best-in-class solutions, with development efforts focused on value-additive features and enhancements to meet the growing needs of the cell analysis market ⁶. These efforts drive innovation across proprietary reagents, software, and services, in addition to new instrumentation releases such as the Cytek Aurora Evo system, the Muse Micro system, and the Enhanced Small Particle (ESP) detection option for its Cytek Aurora, Northern Lights, and Aurora CS systems ⁶.

Another key growth vector is investing in integrated workflow solutions to drive pull-through from consumables and services ⁶. The overarching goal is to become a comprehensive solutions provider by delivering a fully integrated offering of instruments, accessories, consumables, software, and services ⁶. The company is also focused on expanding its bioinformatics offerings, such as Cytek Cloud, a digital ecosystem supporting full spectrum flow cytometry research from panel design to data acquisition ⁶. As market penetration increases, the growing installed base is expected to drive consumable pull-through and recurring revenue ⁶.

The company is deeply committed to driving clinical research application development, particularly within disease detection, diagnosis, and treatment monitoring ⁶. This includes leveraging its platform with complementary cell analysis technologies like Next-Generation Sequencing (NGS) to produce differentiated outcomes with greater sensitivity, such as with minimal residual disease (MRD) testing ⁶. The Northern Lights-CLC system has been registered or approved for clinical use in the European Union and China, and the company plans to pursue regulatory approvals for clinical use of certain products in the United States ⁶.

The company expects its total cost of sales to increase in absolute dollars in future periods, corresponding to anticipated growth in revenue and employee headcount to support manufacturing, operations, field service, and support organizations ⁷⁵. Gross profit in future periods will depend on market conditions impacting pricing, sales mix changes among instruments and service agreements, product mix changes, excess and obsolete inventories, cost structure relative to volume, freight costs, and product warranty obligations ⁷⁵. In the near term, the continued leveraging of fixed manufacturing and service overhead costs, optimization of manufacturing processes, and material cost fluctuations are expected to have the greatest impact on gross margin ⁷⁴. Research and development expense is expected to increase in absolute dollars in future periods due to continued investment in product development ⁷⁹. Sales and marketing expenses are also expected to increase in absolute dollars as the company hires additional personnel, expands sales support infrastructure, and invests in brand and product awareness to penetrate U.S. and international markets ⁷⁹. General and administrative expenses are expected to increase in absolute dollars in future periods due to operating as a public company ⁷⁹.

Planned capital allocation includes continued investment in research and development, with expenses of $36.5 million in 2025 ⁷⁹. The company expects to make additional capital expenditures during the next 12 months, primarily for manufacturing equipment and investment in research and development ⁸⁰. The company had a remaining authorized amount of $35.0 million in its share repurchase program as of December 31, 2025 ⁸¹. The company has never declared or paid cash dividends and does not intend to do so in the foreseeable future, planning to retain all available funds and future earnings to support operations and finance business growth and development ⁶².

Management has flagged several structural headwinds and execution risks. Recent inflation trends may adversely affect the business, financial position, and cash flows, with potential increases in operating costs, labor costs, and R&D costs due to inflationary pressures and supply chain constraints ⁷⁴. Difficult fundraising environments and high interest rates have impacted U.S.-based pharmaceutical and biotech customers, leading to longer sales cycles and adversely affecting operating results in 2025, with potential future impacts ⁷⁴. New U.S. government license requirements announced in January 2025, impacting exports of high-parameter and spectral flow cytometers and cell sorters to certain countries including China, may negatively affect sales, manufacturing, and R&D activities ⁷⁴. Changes in NIH policy regarding grants for academic research, specifically reductions in indirect cost reimbursement, have impacted and may continue to impact revenue from academic and government customers in the near term ⁷⁴.

Geographic, regulatory, and macro factors identified as constraints include multiple, conflicting, and changing international laws and regulations (privacy, tax, export/import restrictions, tariffs, sanctions), difficulties in obtaining and enforcing intellectual property protection, and financial risks from longer payment cycles and foreign currency exchange rate fluctuations ²⁶. International trade disputes, tariffs, and other protectionist measures, particularly between the U.S. and China, may adversely affect sales and profitability, increase manufacturing costs, and reduce demand ²⁶. The imposition of tariffs or trade restrictions could make products less competitive and cause foreign customers to delay purchases or switch to competitors ²⁷. U.S. export controls and sanctions programs could impair the ability to compete internationally due to licensing requirements and potential liability for non-compliance ²⁷. Political and economic instability, including wars and conflicts in the Middle East, also pose risks to international operations ²⁶.

The company faces material risks including the highly competitive cell analysis and life sciences tools market, with established and early-stage competitors like Agilent Technologies, Beckman Coulter, Bio-Rad Laboratories, Standard BioTools, Miltenyi Biotec, Sony Biotechnology, Thermo Fisher Scientific, and Waters Corporation ³⁰. Operational risks include reliance on single or sole-source suppliers for key components like lasers and semiconductors, with qualification of alternative sources potentially taking 12 to 24 months or longer ²⁴. Inaccurate forecasting of customer demand could lead to inventory shortages or excesses, resulting in write-downs or reduced revenue ²⁵. International operations expose the company to business, regulatory, political, operational, financial, and economic risks, including multiple, conflicting, and changing laws, tariffs, export controls, and foreign currency exchange rate fluctuations ²⁶. The U.S. government's new license requirements announced in January 2025, impacting exports of high-parameter and spectral flow cytometers and cell sorters to certain countries including China, may significantly negatively impact sales, manufacturing, and R&D activities ²⁷. Manufacturing capacity increases may involve significant challenges and require additional quality controls and regulatory approvals, and disruptions to manufacturing facilities could impair production ²⁸. Product defects or unexpected performance could increase costs, reduce net sales, and damage reputation, with product warranty accruals of approximately $1.5 million as of December 31, 2025 ³³. The company is subject to stringent and changing U.S. and foreign data privacy and security laws, including GDPR and CCPA, with potential fines of up to 20 million Euros or 4% of annual global revenue under GDPR ⁴⁶. Security incidents, such as the one in November 2025 affecting employee personal information, could lead to regulatory investigations, litigation, fines, and business disruptions ⁴¹. The use of AI and ML technologies in business operations and products presents risks of inaccuracies, biases, legal liability, and regulatory scrutiny, with potential fines of up to 35 million Euros or 7% of total worldwide annual turnover under the EU AI Act ⁴⁹. The company is also exposed to U.S. federal and state anti-fraud and abuse laws, including the Anti-Kickback Statute and False Claims Act, with potential for substantial civil and criminal penalties ⁵⁰. Intellectual property risks include challenges to patents, trademarks, and trade secrets, with 34 issued U.S. utility patents and 70 pending utility patent applications as of December 31, 2025 ¹².

Management's overall tone emphasizes a commitment to innovation and becoming the premier cell analysis company by leveraging its Full Spectrum Profiling (FSP) technology to advance biomedical research and clinical applications ⁷². The company's strategic priorities include accelerating the adoption of its solutions through enhanced sales infrastructure and marketing efforts, continuing to innovate and offer best-in-class solutions with new instruments and enhancements, and investing in integrated workflow solutions to drive recurring revenue from consumables and services ⁶. A key strategic focus is also on driving clinical research application development, particularly in disease detection, diagnosis, and treatment monitoring, and pursuing regulatory approvals for clinical use of its products in the United States ⁶. Management acknowledges that expenses will increase substantially due to attracting and retaining qualified personnel, investing in commercial infrastructure and supporting functions, supporting research and development efforts, expanding geographically, protecting intellectual property, and making strategic investments ⁷³. The company expects its existing cash and cash equivalents and anticipated cash flows from operations to be sufficient to meet working capital and capital expenditure needs for at least the next 12 months from the date of the Annual Report on Form 10-K ⁸⁰.